BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20001169)

  • 1. Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit.
    Rodin HA; Heaton AH; Wilson AR; Garrett NA; Plocher DW
    Am J Manag Care; 2009 Dec; 15(12):881-8. PubMed ID: 20001169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
    Sedjo RL; Cox ER
    Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of alternative interventions on changes in generic dispensing rates.
    O'Malley AJ; Frank RG; Kaddis A; Rothenberg BM; McNeil BJ
    Health Serv Res; 2006 Oct; 41(5):1876-94. PubMed ID: 16987306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA; Avorn J
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation.
    Motheral BR; Henderson R
    Am J Manag Care; 1999 Nov; 5(11):1383-94. PubMed ID: 10662412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate.
    Mager DE; Cox ER
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):347-52. PubMed ID: 17567235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
    Shrank WH; Hoang T; Ettner SL; Glassman PA; Nair K; DeLapp D; Dirstine J; Avorn J; Asch SM
    Arch Intern Med; 2006 Feb; 166(3):332-7. PubMed ID: 16476874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
    Layton S; Barbeau M
    Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of generic-only drug benefits on seniors' medication use and financial burden.
    Tseng CW; Brook RH; Keeler E; Steers WN; Waitzfelder BE; Mangione CM
    Am J Manag Care; 2006 Sep; 12(9):525-32. PubMed ID: 16961441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use.
    Shrank WH; Stedman M; Ettner SL; DeLapp D; Dirstine J; Brookhart MA; Fischer MA; Avorn J; Asch SM
    J Gen Intern Med; 2007 Sep; 22(9):1298-304. PubMed ID: 17647066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlling prescription drug expenditures: a report of success.
    Miller DP; Furberg CD; Small RH; Millman FM; Ambrosius WT; Harshbarger JS; Ohl CA
    Am J Manag Care; 2007 Aug; 13(8):473-80. PubMed ID: 17685828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic substitution of antihypertensive drugs: does it affect adherence?
    Van Wijk BL; Klungel OH; Heerdink ER; de Boer A
    Ann Pharmacother; 2006 Jan; 40(1):15-20. PubMed ID: 16303985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing drug costs: the perception of managed care pharmacy directors.
    Litton LM; Sisk FA; Akins ME
    Am J Manag Care; 2000 Jul; 6(7):805-14. PubMed ID: 11067377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF; Merrell K; Hargrave E; Summer L
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of prescription benefit changes on medical care utilization in a Medicare HMO population.
    Balkrishnan R; Byerly WG; Camacho FT; Shrestha A; Anderson RT
    Am J Manag Care; 2001 Nov; 7(11):1093-100. PubMed ID: 11725812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
    Tungol A; Starner CI; Gunderson BW; Schafer JA; Qiu Y; Gleason PP
    J Manag Care Pharm; 2012; 18(9):690-700. PubMed ID: 23206212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of patient and plan design factors on switching to preferred statin therapy.
    Cox ER; Kulkarni A; Henderson R
    Ann Pharmacother; 2007 Dec; 41(12):1946-53. PubMed ID: 17971409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing patient drug acquisition costs can lower diabetes health claims.
    Mahoney JJ
    Am J Manag Care; 2005 Aug; 11(5 Suppl):S170-6. PubMed ID: 16111439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.